Advertisement

Topics

DBV and Aimmune poised to dominate peanut allergy market

07:21 EST 19 Jan 2018 | Net Resources International

Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV Technologies and Aimmune Therapeutics—presented to investors at...
Read More...

The post DBV and Aimmune poised to dominate peanut allergy market appeared first on Drug Development Technology.

Original Article: DBV and Aimmune poised to dominate peanut allergy market

NEXT ARTICLE

More From BioPortfolio on "DBV and Aimmune poised to dominate peanut allergy market"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...